Abstract
Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4,732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 389-395 |
| Number of pages | 7 |
| Journal | Cerebrovascular Diseases |
| Volume | 16 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2003 |
Keywords
- Atorvastatin
- Cholesterol
- Lipid
- Statin
- Stroke
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
- Cardiology and Cardiovascular Medicine
Access to Document
Fingerprint Dive into the research topics of 'Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study'. Together they form a unique fingerprint.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. / Sillesen, Henrik; Albers, Gregory; Altafullah, Irfan; Benavente, Oscar; Book, Diane; Broderick, Joseph; Calder, Christopher; Callahan, Alfred S.; Carlini, Walter; Chaturvedi, Seemant; Chippendale, Thomas; Clark, Wayne; Collins, Greg; Coull, Bruce; Davis, Patricia; Devlin, Thomas; Dick, Arthur R.; Dirr-Ledbetter, Lucy Younger; Dooneief, George; Duff, R. Scott; Estronza, Nordeli; Forteza, Alejandro; Frankel, Michael R.; Frey, James L.; Friday, Gary; Goldstein, Jerome; Goldstein, Steven; Graham, Gleen; Harper, Wayne; Harris, Jonathan; Hendin, Barry; Hess, David C.; Hinton, Richard; Hollander, Joshua; Hsu, Chung Y.; Hughes, Richard L.; Kasner, Scott; Kent, T. A.; Kim, Lance; Kirshner, Howard; LaMonte, Marian; Levin, Kenneth; Libman, Richard; McDowell, Paul; McGee, Francis E.; Meyer, Brett; Minagar, Alireza; Munschauer, Frederick E.; Munson, Richard; Nash, Marshall; Orr, Sean C.; Ratinov, Gerald; Salanga, Virgilio; Sen, Souvik; Silliman, Scott; Singer, Richard; Smith, Don; Sullivan, Herman; Thaler, David; Tietjen, Gretchen; Tuchman, Michael; Uskavitch, David; Verro, Piero; Vicari, Ralph; Weinstein, Richard; Wilterdink, Janet; Zweifler, Richard; Beaudry, Michael; Cote, Robert; Hoyte, Keith; Lebrun, Louise Helene; Norris, John; Selchen, Daniel; Shuaib, Ashfaq; Simard, Denis; Spence, David; Teal, Philip; Winger, Michael; Schmidt, Reinhold; Pramsohler, Bruno; Schmidauer, Christoph; Kaste, Markku; Sivenius, Juhani; Wagner, Anna; Terent, Andreas; Amarenco, Pierre; Milandre, Loic; Chollet, Francois; de Broucker, Thomas; Moulin, Thierry; Roullet, Etienne; Leys, Didier; Mahagne, Marie Helene; Hennerici, Michael; Heiss, W. D.; Busse, Otto; Haberl, Roman; Harms, L.; Diener, C.; Hamann, G.; Ringelstein, E. Bemd; Canal, Nicola; Capurso, Antonio; Mamoli, Angelo; Frattola, Lodovico; Gandolfo, Carlo; Senin, Umberto; Zito, Michele; de Keyser, Keyser; Netherlands, The; Koudstaal, P. J.; Haas, J. A.; de Jong, G.; Bogousslavsky, Julien; Mattie, Heinrich; Baumgartner, Ralf; MacWalter, R. S.; Dijkhuizen, Roelfe; Ekpo, Enefioke Ben; Bath, Philip; Lees, Kennedy R.; Ferro, Jose; Cunha, Luis; Davalos, Antonio; Chamorro, Angel; Sabin, Alvarez; Jimenez, Dolores; Gonzalez, Jose Ramon; Lago, Aida; Egido, Jose; Vivancos, Jose; Guiu, Matias; Dorman, Geoffrey; Davis, Stephen; Gilles, David; Frayne, Judy; Crimmins, Denis; Dimmit, Simon; Singh, Gagrath Pradeep; Scott, Russell; Anderson, Neil Edward; Carr, J.; Kruger, A. K.; Gardiner, J.
In: Cerebrovascular Diseases, Vol. 16, No. 4, 2003, p. 389-395.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study
AU - Sillesen, Henrik
AU - Albers, Gregory
AU - Altafullah, Irfan
AU - Benavente, Oscar
AU - Book, Diane
AU - Broderick, Joseph
AU - Calder, Christopher
AU - Callahan, Alfred S.
AU - Carlini, Walter
AU - Chaturvedi, Seemant
AU - Chippendale, Thomas
AU - Clark, Wayne
AU - Collins, Greg
AU - Coull, Bruce
AU - Davis, Patricia
AU - Devlin, Thomas
AU - Dick, Arthur R.
AU - Dirr-Ledbetter, Lucy Younger
AU - Dooneief, George
AU - Duff, R. Scott
AU - Estronza, Nordeli
AU - Forteza, Alejandro
AU - Frankel, Michael R.
AU - Frey, James L.
AU - Friday, Gary
AU - Goldstein, Jerome
AU - Goldstein, Steven
AU - Graham, Gleen
AU - Harper, Wayne
AU - Harris, Jonathan
AU - Hendin, Barry
AU - Hess, David C.
AU - Hinton, Richard
AU - Hollander, Joshua
AU - Hsu, Chung Y.
AU - Hughes, Richard L.
AU - Kasner, Scott
AU - Kent, T. A.
AU - Kim, Lance
AU - Kirshner, Howard
AU - LaMonte, Marian
AU - Levin, Kenneth
AU - Libman, Richard
AU - McDowell, Paul
AU - McGee, Francis E.
AU - Meyer, Brett
AU - Minagar, Alireza
AU - Munschauer, Frederick E.
AU - Munson, Richard
AU - Nash, Marshall
AU - Orr, Sean C.
AU - Ratinov, Gerald
AU - Salanga, Virgilio
AU - Sen, Souvik
AU - Silliman, Scott
AU - Singer, Richard
AU - Smith, Don
AU - Sullivan, Herman
AU - Thaler, David
AU - Tietjen, Gretchen
AU - Tuchman, Michael
AU - Uskavitch, David
AU - Verro, Piero
AU - Vicari, Ralph
AU - Weinstein, Richard
AU - Wilterdink, Janet
AU - Zweifler, Richard
AU - Beaudry, Michael
AU - Cote, Robert
AU - Hoyte, Keith
AU - Lebrun, Louise Helene
AU - Norris, John
AU - Selchen, Daniel
AU - Shuaib, Ashfaq
AU - Simard, Denis
AU - Spence, David
AU - Teal, Philip
AU - Winger, Michael
AU - Schmidt, Reinhold
AU - Pramsohler, Bruno
AU - Schmidauer, Christoph
AU - Kaste, Markku
AU - Sivenius, Juhani
AU - Wagner, Anna
AU - Terent, Andreas
AU - Amarenco, Pierre
AU - Milandre, Loic
AU - Chollet, Francois
AU - de Broucker, Thomas
AU - Moulin, Thierry
AU - Roullet, Etienne
AU - Leys, Didier
AU - Mahagne, Marie Helene
AU - Hennerici, Michael
AU - Heiss, W. D.
AU - Busse, Otto
AU - Haberl, Roman
AU - Harms, L.
AU - Diener, C.
AU - Hamann, G.
AU - Ringelstein, E. Bemd
AU - Canal, Nicola
AU - Capurso, Antonio
AU - Mamoli, Angelo
AU - Frattola, Lodovico
AU - Gandolfo, Carlo
AU - Senin, Umberto
AU - Zito, Michele
AU - de Keyser, Keyser
AU - Netherlands, The
AU - Koudstaal, P. J.
AU - Haas, J. A.
AU - de Jong, G.
AU - Bogousslavsky, Julien
AU - Mattie, Heinrich
AU - Baumgartner, Ralf
AU - MacWalter, R. S.
AU - Dijkhuizen, Roelfe
AU - Ekpo, Enefioke Ben
AU - Bath, Philip
AU - Lees, Kennedy R.
AU - Ferro, Jose
AU - Cunha, Luis
AU - Davalos, Antonio
AU - Chamorro, Angel
AU - Sabin, Alvarez
AU - Jimenez, Dolores
AU - Gonzalez, Jose Ramon
AU - Lago, Aida
AU - Egido, Jose
AU - Vivancos, Jose
AU - Guiu, Matias
AU - Dorman, Geoffrey
AU - Davis, Stephen
AU - Gilles, David
AU - Frayne, Judy
AU - Crimmins, Denis
AU - Dimmit, Simon
AU - Singh, Gagrath Pradeep
AU - Scott, Russell
AU - Anderson, Neil Edward
AU - Carr, J.
AU - Kruger, A. K.
AU - Gardiner, J.
N1 - Copyright: Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2003
Y1 - 2003
N2 - Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4,732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention.
AB - Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4,732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention.
KW - Atorvastatin
KW - Cholesterol
KW - Lipid
KW - Statin
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=0141676273&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141676273&partnerID=8YFLogxK
U2 - 10.1159/000072562
DO - 10.1159/000072562
M3 - Article
C2 - 14584489
AN - SCOPUS:0141676273
VL - 16
SP - 389
EP - 395
JO - Cerebrovascular Diseases
JF - Cerebrovascular Diseases
SN - 1015-9770
IS - 4
ER -